MarketPulse

Mucopolysaccharidosis Type I

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Gene Therapy Stock Faces Class Action as FDA Halts REGENXBIO Trial Over Safety Concerns

REGENXBIO faces class action lawsuit after FDA halted RGX-111 gene therapy trial due to CNS tumor, triggering 18% stock decline.
RGNXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Lawsuit Targets REGENXBIO Over RGX-111 Gene Therapy Disclosures

Investors in $REGENXBIO face class action lawsuit alleging false statements about RGX-111 gene therapy development and clinical trial results spanning 2022-2026.
RGNXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Gene Therapy Giant REGENXBIO Faces Class Action Over RGX-111 Misstatements

Class action lawsuit filed against REGENXBIO alleging false statements about RGX-111 gene therapy. Covers investors from Feb 2022 to Jan 2026; lead plaintiff deadline April 14.
RGNXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Lawsuit Targets REGENXBIO Over Gene Therapy Claims

REGENXBIO faces class action lawsuit alleging executives made false statements about RGX-111 gene therapy's efficacy and safety, seeking shareholder damages.
RGNXsecurities fraudclass action lawsuit